IPO registrations (S-1, F-1) · Registrants
Evommune, Inc.
- SEC CIK
- 2044725 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2025-10-09, last 2026-04-17; 2 initial registrations, 1 amendment
- Outcome
- Final prospectus filed 2025-11-06; declared effective 2026-04-24
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1891 PAGE MILL RD, Palo Alto, CA
- EIN
- 85-0742575
- Ticker
- EVMN (NYSE)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Evommune, Inc. on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per share (S-1/A filed 2025-10-17)
- Final price
- $16.00 per share, within the range (424B4 filed 2025-11-06, an initial public offering)
- Shares sold
- 9,375,000
- Gross proceeds
- $150,000,000 before underwriting discounts and any over-allotment option
- Listing
- NYSE under the symbol EVMN
- Lead underwriters
- Morgan Stanley; Leerink Partners (2,625,000 shares); Evercore (1,968,750 shares); Cantor Fitzgerald (1,312,500 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: EVOMMUNE, INC. EXACT (EIN (EXACT))
- Form D issuer: Evommune, Inc. EXACT (CIK (EXACT))
- SEC filer: Evommune, Inc. EXACT (CIK (EXACT))
- Person page: Luis C Pena Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 5
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2025-10-09 | S-1 | S-1 (registration) | Evommune, Inc. | 0001193125-25-235673 ↗ |
| 2025-10-17 | S-1/A | S-1/A (amendment) | Evommune, Inc. | 0001193125-25-242492 ↗ |
| 2025-11-06 | 424B4 | 424B4 (final prospectus) | Evommune, Inc. | 0001193125-25-270066 ↗ |
| 2026-04-17 | S-1 | S-1 (registration) | Evommune, Inc. | 0001193125-26-161516 ↗ |
| 2026-04-24 | EFFECT | EFFECT (declared effective) | Evommune, Inc. | 9999999995-26-001330 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-17 | S-1/A | registration statement | $15.00–$17.00 | 9,375,000 | - | NYSE EVMN | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2025-11-06 | 424B4 | final prospectus | $16.00 | 9,375,000 | $150,000,000 | NYSE EVMN | 4 | primary document; price sentence, shares sentence, proceeds table, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bauer Eugene | Director,Officer | Chief Medical Officer | 5 | 2025–2026 | |
| Carver Kyle | Officer | Chief Financial Officer | 7 | 2025–2026 | |
| Cohen David E | Director | 4 | 2025–2026 | ||
| DiRocco Derek | Director | 1 | 2025 | ||
| Drew Janice Suzann | Officer | Chief of Dev. Operations; EVP, Operations | 6 | 2025–2026 | |
| Hopfner Robert Lorne | Director,TenPercentOwner | 3 | 2025 | ||
| KIRSCH ARTHUR S | Director | 4 | 2025–2026 | ||
| Kolchinsky Peter | Director; Director,TenPercentOwner | 2 | 2025–2026 | ||
| LSP 7 Cooperative UA | Director,TenPercentOwner; TenPercentOwner | 3 | 2025–2026 | ||
| MCGRAW BENJAMIN F III | Director | 3 | 2025–2026 | ||
| Moss Gregory S. | Officer | Chief Business & Legal Officer | 6 | 2025–2026 | |
| Patel Jeegar Pravinkumar | Officer | Chief Scientific Officer | 7 | 2025–2026 | |
| Pena Luis C. | Director,Officer | President & CEO | 7 | 2025–2026 | person page Fuzzy |
| Pivotal bioVenture Partners Fund I G.P., L.P. | Director,TenPercentOwner | 2 | 2025 | ||
| Pivotal bioVenture Partners Fund I, L.P. | Director,TenPercentOwner | 2 | 2025 | ||
| Pivotal bioVenture Partners Fund I U.G.P. Ltd | Director,TenPercentOwner | 2 | 2025 | ||
| RA Capital Healthcare Fund LP | Director; Director,TenPercentOwner | 2 | 2025–2026 | ||
| RA CAPITAL MANAGEMENT, L.P. | Director; Director,TenPercentOwner | 3 | 2025–2026 | ||
| RA Capital Nexus Fund III, L.P. | Director | 2 | 2025–2026 | ||
| Shah Rajeev M. | Director; Director,TenPercentOwner | 2 | 2025–2026 | ||
| Verduyn-van Weegen Felice Isabel | Director,TenPercentOwner | 3 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-01-08 | Evommune, Inc. | Other | $115,499,956 | $115,499,956 | 25 | 1 |
| 2025-01-08 | Evommune, Inc. | Other | $57,500,000 | $57,500,000 | 16 | 1 |
| 2025-01-08 | Evommune, Inc. | Other | $84,449,985 | $81,799,952 | 10 | 1 |
| 2025-01-07 | Evommune, Inc. | Other | $12,462,474 | $12,462,474 | 18 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | EVOMMUNE, INC. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Evommune, Inc. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | Evommune, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Evommune, Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | EVOMMUNE, INC. | EIN (EXACT) | ||
| Person page | Luis C Pena | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- NovaCardia Inc CA
- MyoKardia, Inc. CA
- Bioquest Corp CA
- Regen BioPharma Inc CA
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- Diadexus, Inc. CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health